FUB-APINACA
Chemical compound
- CA: Schedule II
- DE: NpSG (Industrial and scientific use only)
- UK: Class B
- US: Schedule I
- N-(Adamantan-1-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamide
- 2180933-90-6
Y
- 118796517
- 30922497
- OF9Q7PH4UD
- Interactive image
- O=C(NC1(C[C@H]2C3)C[C@H]3C[C@H](C2)C1)C4=NN(CC5=CC=C(F)C=C5)C6=C4C=CC=C6
InChI
- InChI=1S/C25H26FN3O/c26-20-7-5-16(6-8-20)15-29-22-4-2-1-3-21(22)23(28-29)24(30)27-25-12-17-9-18(13-25)11-19(10-17)14-25/h1-8,17-19H,9-15H2,(H,27,30)/t17-,18+,19-,25?
- Key:MWBHSNBPUSKVDD-LPSAYFBNSA-N
FUB-APINACA (also known as A-FUBINACA according to the EMCCDA framework for naming synthetic cannabinoids[1] and FUB-AKB48) is an indazole-based synthetic cannabinoid that is presumed to be a potent agonist of the CB1 receptor and has been sold online as a designer drug.[2] It is an analog of APINACA and 5F-APINACA where the pentyl chain has been replaced with fluorobenzyl.
Pharmacology
FUB-APINACA acts as a full agonist with a binding affinity of 1.06 nM at CB1 and 0.174 nM at CB2 cannabinoid receptors.[3]
Legal status
In the United States, FUB-APINACA was temporarily emergency scheduled by the DEA in 2019.[4] and made a permanent Schedule I Controlled Substance nationwide on April 7, 2022.[5] Previously, it was illegal only in Alabama (listed as FUB-AKB48).[6]
Sweden's public health agency suggested classifying FUB-APINACA as a hazardous substance on November 10, 2014.[7]
See also
References
- ^ Pulver B, Fischmann S, Gallegos A, Christie R. EMCDDA framework and practical guidance for naming synthetic cannabinoids. Drug Test Anal. 2023;15(3): 255‐276. doi:10.1002/dta.3403
- ^ "FUB-AKB48". Cayman Chemical. Retrieved 23 July 2015.
- ^ Hess C, Schoeder CT, Pillaiyar T, Madea B, Müller CE (2016). "Pharmacological evaluation of synthetic cannabinoids identified as constituents of spice". Forensic Toxicology. 34 (2): 329–343. doi:10.1007/s11419-016-0320-2. PMC 4929166. PMID 27429655.
- ^ "Schedules of Controlled Substances: Temporary Placement of 5F-EDMB-PINACA, 5F-MDMB-PICA, FUB-AKB48, 5F-CUMYL-PINACA, and FUB-144 into Schedule I". Federal Register. 2019-04-16.
- ^ "Schedules of Controlled Substances: Placement of 5F-EDMB-PINACA, 5FMDMB-PICA, FUB-AKB48, 5F-CUMYLPINACA, and FUB-144 in Schedule I" (PDF). Federal Register. 87 (67). 7 April 2022.
- ^ Alabama Senate Bill SB 333: Controlled Substances
- ^ "Cannabinoider föreslås bli klassade som hälsofarlig vara". Folkhälsomyndigheten. Retrieved 23 July 2015.
- v
- t
- e
(comparison)
| Cannabibutols |
|
|---|---|
| Cannabichromenes | |
| Cannabicyclols |
|
| Cannabidiols | |
| Cannabielsoins |
|
| Cannabigerols | |
| Cannabiphorols |
|
| Cannabinols | |
| Cannabitriols |
|
| Cannabivarins |
|
| Delta-8-tetrahydrocannabinols |
|
| Delta-9-tetrahydrocannabinols | |
| Delta-10-Tetrahydrocannabinols | |
| Miscellaneous cannabinoids |
|
| Active metabolites |
- Arachidonoyl ethanolamide (AEA; anandamide)
- 2-Arachidonoylglycerol (2-AG)
- 2-Arachidonyl glyceryl ether (2-AGE; noladin ether)
- 2-Oleoylglycerol (2-OG)
- N-Arachidonoyl dopamine (NADA)
- N-Arachidonylglycine (NAGly)
- 2-Arachidonoyl lysophosphatidylinositol (2-ALPI)
- N-Arachidonoyl serotonin (AA-5-HT)
- Docosatetraenoylethanolamide (DEA)
- Lysophosphatidylinositol (LPI)
- Oleamide
- Oleoylethanolamide (OEA)
- Palmitoylethanolamide (PEA)
- RVD-Hpα
- Stearoylethanolamide (SEA)
- O-Arachidonoyl ethanolamine (O-AEA; virodhamine)
cannabinoid
receptor
agonists /
neocannabinoids
| Classical cannabinoids (dibenzopyrans) |
|
|---|---|
| Non-classical cannabinoids |
|
| Adamantoylindoles |
|
| Benzimidazoles | |
| Benzoylindoles |
|
| Cyclohexylphenols | |
| Eicosanoids |
|
| Hydrocarbons | |
| Indazole carboxamides | |
| Indazole-3- carboxamides |
|
| Indole-3-carboxamides |
|
| Indole-3-carboxylates | |
| Naphthoylindazoles | |
| Naphthoylindoles |
|
| Naphthoylpyrroles | |
| Naphthylmethylindenes | |
| Naphthylmethylindoles | |
| Phenylacetylindoles | |
| Pyrazolecarboxamides |
|
| Pyrrolobenzoxazines | |
| Quinolinyl esters | |
| Tetramethylcyclo- propanoylindazoles | |
| Tetramethylcyclo- propanoylindoles | |
| Tetramethylcyclo- propylindoles | |
| Others |
|
enhancers
(inactivation inhibitors)
- 4-Nonylphenylboronic acid
- AM-404
- Arachidonoyl serotonin
- Arvanil
- BIA 10-2474
- Biochanin A
- CAY-10401
- CAY-10429
- Genistein
- Guineesine
- IDFP
- JNJ 1661010
- JNJ-42165279
- JZL184
- JZL195
- Kaempferol
- LY-2183240
- MK-4409
- O-1624
- O-2093
- Oleoylethanolamide (OEA)
- Olvanil
- Palmitoylethanolamide (PEA)
- PF-04457845
- PF-622
- PF-750
- PF-3845
- PHOP
- URB-447
- URB-597
- URB-602
- URB-754
- VDM-11
(antagonists/inverse
agonists/antibodies)
- AM-251
- AM-281
- AM-630
- AM-1387
- AM-4113
- AM-6527
- AM-6545
- BML-190
- Brizantin (Бризантин)
- CAY-10508
- CB-25
- CB-52
- CB-86
- Dietressa (Диетресса)
- Drinabant (AVE1625)
- Hemopressin
- Ibipinabant (SLV319)
- JTE-907
- LH-21
- LY-320,135
- MDA-77
- MJ-15
- MK-9470
- NESS-0327
- NIDA-41020
- O-606
- O-1184
- O-1248
- O-1918
- O-2050
- O-2654
- Otenabant (CP-945,598)
- PF-514273
- PipISB
- PSB-SB-487
- Rimonabant (SR141716)
- Rosonabant (E-6776)
- SR-144,528
- Surinabant (SR147778)
- Taranabant (MK-0364)
- TM-38837
- VCHSR
- See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
- List of: AM cannabinoids
- JWH cannabinoids
- Designer drugs § Synthetic cannabimimetics
